How India Exports Cetuximab to the World

As of March 2026, cetuximab is approved in the United States under the brand name Erbitux, originally approved by the FDA in February 2004. The FDA's Orange Book lists cetuximab as a reference listed drug (RLD), indicating its status as the standard for generic versions. To date, no generic versions of cetuximab have received FDA approval, underscoring the absence of approved Abbreviated New Drug Applications (ANDAs) for this biologic.

The regulatory pathway for biosimilars in the U.S. involves a rigorous evaluation to demonstrate biosimilarity to the reference product. Given the complexity of biologics like cetuximab, the approval process is stringent, contributing to the current lack of approved biosimilar versions. This regulatory environment presents both challenges and opportunities for Indian exporters aiming to enter the U.S. market.

In the European Union, cetuximab is authorized under the brand name Erbitux, with the European Medicines Agency (EMA) granting marketing authorization in June 2004. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has also approved cetuximab for similar indications. Manufacturers exporting cetuximab to these markets must comply with EU Good Manufacturing Practice (GMP) standards, ensuring product quality and safety. Additionally, post-Brexit, the UK has established its own regulatory requirements, necessitating adherence to both EU and UK-specific guidelines for market entry.

As of the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, cetuximab is not included. The WHO's selection criteria focus on medicines that address priority health needs, considering factors such as efficacy, safety, and cost-effectiveness. While cetuximab is recognized for its therapeutic benefits, its exclusion may be attributed to considerations like cost and accessibility in various healthcare settings. Regarding pharmacopoeial standards, cetuximab is included in major compendia such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP), providing standardized quality benchmarks for its production and quality control.

In India, cetuximab is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, cetuximab is not listed under the DPCO, allowing manufacturers to set prices based on market dynamics. For export purposes, the Central Drugs Standard Control Organization (CDSCO) requires a No Objection Certificate (NOC), ensuring that the exported product meets quality and regulatory standards.

Cetuximab's primary patents have expired in major markets, including the U.S. and the EU, opening avenues for biosimilar development. However, the absence of approved biosimilars indicates the challenges associated with replicating complex biologics. The competitive landscape remains limited, with the original manufacturer maintaining a significant market share.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines. The 24th edition, published in September 2025, did not include cetuximab, reflecting ongoing evaluations of its global health impact and accessibility. (who.int)

In January 2026, the WHO emphasized the importance of essential medicines in achieving universal health coverage, highlighting the need for medicines that are effective, safe, and affordable. This underscores the challenges associated with high-cost biologics like cetuximab in resource-limited settings. (who.int)

These developments highlight the dynamic nature of the pharmaceutical regulatory landscape, emphasizing the need for continuous monitoring and adaptation by stakeholders involved in the production and export of cetuximab.

Cetuximab, a monoclonal antibody used in oncology, relies on complex biotechnological processes for its Active Pharmaceutical Ingredient (API) production. While India has developed capabilities in biopharmaceutical manufacturing, the production of Key Starting Materials (KSMs) and certain intermediates often depends on imports, particularly from China. This dependency is significant, as China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the sector.

Historical events underscore the risks associated with this reliance. For instance, in 2018, environmental regulatory actions in China led to the shutdown of numerous chemical plants, causing substantial disruptions in the supply of KSMs and intermediates. This resulted in price hikes and supply shortages for various APIs globally. Such incidents highlight the vulnerability of supply chains that are heavily dependent on a single country for critical raw materials.

Analysis of TransData Nexus's proprietary trade data from 2022 to 2026 reveals that the top five Indian exporters of Cetuximab account for 30.8% of total export value, with VAMA LIFECARE PRIVATE LIMITED leading at an 11.4% share. This indicates a moderate level of supplier concentration. While a diversified exporter base can mitigate risks, the reliance on a few key suppliers still poses potential vulnerabilities, especially if any of these entities face operational challenges.

To address such dependencies, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic manufacturing of critical APIs and KSMs. By 2025, significant investments were made under this scheme to reduce import reliance and enhance self-sufficiency in pharmaceutical production. However, the effectiveness of these initiatives in fully mitigating supply chain risks remains to be seen.

Geopolitical tensions and shipping disruptions have increasingly impacted global supply chains. The Red Sea and the Strait of Hormuz are critical maritime routes for pharmaceutical exports. Any instability in these regions can lead to delays and increased shipping costs. Additionally, escalating tensions between major economies, such as the United States and China, have resulted in trade restrictions and tariffs, further complicating the supply chain landscape.

Regulatory bodies like the FDA and EMA have issued alerts regarding potential drug shortages stemming from these disruptions. For example, in February 2026, the FDA highlighted vulnerabilities in the supply of certain oncology drugs due to geopolitical factors affecting raw material availability. Such warnings underscore the need for proactive risk management strategies in pharmaceutical supply chains.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on any single source for APIs and KSMs.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical raw materials to decrease reliance on imports.

• Monitor Geopolitical Developments: Establish a dedicated team to track international political events and assess their potential impact on supply chains.

• Develop Contingency Plans: Create robust plans to address potential disruptions, including alternative shipping routes and emergency stockpiles.

• Collaborate with Regulatory Bodies: Maintain open communication with agencies like the FDA and EMA to stay informed about potential shortages and compliance requirements.

RISK_LEVEL: MEDIUM